A Skin Patch Immunotherapy Can Desensitize Toddlers with Peanut Allergy: New Innovation
A global phase 3 clinical trial, including Ann & Robert H. Lurie Children’s Hospital of Chicago, has yielded promising results in desensitizing toddlers with peanut allergy through a year-long immunotherapy treatment using a skin patch. The trial, funded by DBV Technologies and published in the New England Journal of Medicine, demonstrated a significant reduction in the risk of severe allergic reactions caused by accidental exposure to peanuts in children aged 1-3 years.
Promising Outcomes and Increased Tolerance
The randomized, double-blind, placebo-controlled trial conducted at Lurie Children’s Hospital revealed encouraging findings. Toddlers who initially reacted to small amounts of peanuts were able to tolerate the equivalent of one to four peanuts after completing the immunotherapy treatment. This increased tolerance significantly enhances their protection against inadvertent peanut exposure. Moreover, the study indicated that the peanut patch was safe, with minimal risk of severe allergic reactions. These results bring great relief to families of children affected by peanut allergies.
Addressing a Widespread Issue
Peanut allergy affects approximately 2 percent of children in countries such as the United States, Canada, and other Westernized nations. It is a persistent condition that often continues into adulthood. Even trace amounts of peanuts, including those present in products manufactured on shared equipment, can trigger life-threatening allergic reactions. Notably, there are currently no approved treatments for peanut-allergic children under the age of 4.
Expanding Clinical Trials and Advancing Treatment Options
Lurie Children’s Hospital has been at the forefront of food allergy research since 2012. Their clinical trials program has played a crucial role in evaluating novel treatments, including oral immunotherapy for peanuts, which has received approval from the Food and Drug Administration (FDA). Ongoing trials cater to patients of all age groups, ranging from infants to young adults. The program, led by Principal Investigators Elizabeth Lippner, MD, and Abigail Lang, MD, MSCI, continues to push the boundaries of pediatric medicine and improve child health.
Conclusion
The groundbreaking phase 3 clinical trial conducted at Ann & Robert H. Lurie Children’s Hospital of Chicago, published in the New England Journal of Medicine, highlights the effectiveness and safety of skin patch immunotherapy in desensitizing toddlers with peanut allergy. This innovative approach has demonstrated a significant reduction in the risk of severe allergic reactions caused by accidental peanut exposure. With ongoing research and expanding clinical trials, Lurie Children’s Hospital remains committed to advancing treatment options and improving the lives of children affected by food allergies.
Ann & Robert H. Lurie Children’s Hospital of Chicago published the study. Note: Content may be edited for style and length.
For more interesting news and facts, check out our blog New Facts World and follow us on Instagram.
